Journal
PATHOGENS
Volume 11, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/pathogens11111291
Keywords
host-directed therapy; tuberculosis; Mycobacterium tuberculosis; drug repositioning
Categories
Funding
- Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science, and Technology [2020R1I1A1A01066916, 2021R1A2C1004525]
- National Research Foundation of Korea [2020R1I1A1A01066916, 2021R1A2C1004525] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Tuberculosis (TB) is a major cause of death globally and poses a continuous threat to public health. Conventional TB treatment is associated with long-term treatment regimens and side effects. With the emergence of drug-resistant TB, there is an urgent need for the development of new treatment strategies. This article introduces host-directed therapy (HDT) as an alternative approach that modulates host immune responses to effectively treat TB.
Tuberculosis (TB) is one of the leading causes of death worldwide, consistently threatening public health. Conventional tuberculosis treatment requires a long-term treatment regimen and is associated with side effects. The efficacy of antitubercular drugs has decreased with the emergence of drug-resistant TB; therefore, the development of new TB treatment strategies is urgently needed. In this context, we present host-directed therapy (HDT) as an alternative to current tuberculosis therapy. Unlike antitubercular drugs that directly target Mycobacterium tuberculosis (Mtb), the causative agent of TB, HDT is an approach for treating TB that appropriately modulates host immune responses. HDT primarily aims to enhance the antimicrobial activity of the host in order to control Mtb infection and attenuate excessive inflammation in order to minimize tissue damage. Recently, research based on the repositioning of drugs for use in HDT has been in progress. Based on the overall immune responses against Mtb infection and the immune-evasion mechanisms of Mtb, this review examines the repositioned drugs available for HDT and their mechanisms of action.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available